SN
SNZZF.US Senzime AB (publ)
- Market cap
- USD 46.3M
- P/E
- -
- P/B
- 1.46x
- ROE
- -28.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SNZZF.US undervalued?
Graham numberThe Graham number of Senzime AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Senzime AB (publ) fundamental analysis
No fundamental analysis for Senzime AB (publ) yet.
Senzime AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Senzime AB (publ)
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue's opposition to carrying an alternating electri…
Full company profileSenzime AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Senzime AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.63M | 189K | 3.21M | 6.71M | 9.34M | 11.0M | 14.0M | 35.8M | 58.5M | 104M | 104M |
| Gross Profit | 1.10M | -556K | -5.23M | 3.87M | -7.90M | -4.92M | -4.40M | 8.34M | 20.1M | 34.7M | 49.8M |
| Operating Income | -9.41M | -13.0M | -26.8M | -36.4M | -47.2M | -85.1M | -138M | -134M | -131M | -120M | -84.6M |
| EBITDA | - | -12.7M | -21.3M | -24.0M | -37.0M | -73.2M | -118M | -116M | -95.6M | -115M | -49.7M |
| Net Income | -9.41M | -13.0M | -25.6M | -33.7M | -47.4M | -82.1M | -133M | -134M | -119M | -137M | -73.5M |
| EPS | - | -0.32 | -0.52 | -0.64 | -0.76 | -1.31 | -1.87 | -1.12 | -0.89 | -0.87 | -0.47 |
| Balance Sheet | |||||||||||
| Total Assets | 156M | 166M | 197M | 188M | 259M | 175M | 323M | 434M | 425M | 370M | 316M |
| Total Liabilities | 24.4M | 25.6M | 29.7M | 24.1M | 27.5M | 24.0M | 60.8M | 58.1M | 78.7M | 65.4M | 61.3M |
| Shareholders' Equity | 132M | 140M | 167M | 164M | 231M | 151M | 262M | 375M | 346M | 304M | 254M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 30.9M | 160M | 74.9M | 26.0M | 151M | 101M | 74.0M | 28.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -10.0M | -12.3M | -17.4M | -26.6M | -38.3M | -81.3M | -137M | -114M | -106M | -109M | -57.3M |
| Capital Expenditure | 28.0K | 211K | 192K | 192K | 192K | 1.17M | 979K | 6.89M | 20.3M | 18.1M | 11.9M |
| Free Cash Flow | - | -22.3M | -27.2M | -30.9M | -38.7M | -84.3M | -142M | -121M | -126M | -127M | -69.3M |
| Ratios | |||||||||||
| ROE | -7.1% | -9.3% | -15.3% | -20.6% | -20.5% | -54.6% | -50.7% | -35.7% | -34.3% | -45.1% | -28.9% |
| ROA | -6.0% | -7.8% | -13.0% | -17.9% | -18.3% | -47.0% | -41.1% | -30.9% | -28.0% | -37.2% | -23.3% |
| Net Profit Margin | -578.1% | -6,892.6% | -797.2% | -501.8% | -508.1% | -748.1% | -945.6% | -375.2% | -203.0% | -132.1% | -70.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Senzime AB (publ) dividends
Senzime AB (publ) has not paid dividends in the last 9 fiscal years.
Last stock split: 1013:1000 on Jun 22, 2023.
Who owns Senzime AB (publ)
- Insiders 42.39%
- Institutions 22.76%
- Public & others 34.86%
- Shares outstanding 157M
- Free float 107M
Senzime AB (publ) company profile
- Company name
- Senzime AB (publ)
- Ticker
- SNZZF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 59
- Fiscal year end
- December
- Address
- Verkstadsgatan 8, Uppsala, Sweden, 753 23
- Phone
- 46 18 51 56 40
- Website
- senzime.com
About Senzime AB (publ)
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue's opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe. The company has a strategic connectivity and licensing agreement with Masimo that grants Senzime the rights to use some of Masimo's intellectual property; license agreement with Fukuda Denshi Co. Ltd. to license TetraGraph technology; and license agreement with CoreSpiron (Henan) Co Ltd. to manufacture and sell ExSpiron system. Senzime AB (publ) was incorporated in 1999 and is headquartered in Uppsala, Sweden.
Senzime AB (publ) management
8- Mr. Philip SibergChief Executive Officer · born 1973
- Mr. Slavoljub GrujicicChief Financial Officer · born 1970
- Ms. Johanna TulkkiExecutive VP & COO · born 1970
- Mr. Anders JacobsonChief Scientific Officer · born 1967
- Ms. Paula TreutigerHead of Communication & Investor Relations · born 1967
- Mr. Michael NobleChief Marketing Officer · born 1988
- Ms. Catrin MolundExecutive Vice President of Business Development · born 1970
- Ms. Johanna FarisHead of Q/RA/S · born 1975